{"ticker": {"uuid": "4f654c8d-43ca-4af2-9cef-79ff430129a0", "symbol": "KOD", "name": "Kodiak Sciences Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Dow, S&P 500, Nasdaq Futures Rise After Trump\u2019s 10-Day Iran Pause: Why META, DJT, U, KOD, MDGL Are Trending After-Hours", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOZFFaTFpONXJlMV9wR2hQSU5mRTU3S3FQWjYwVmxSNFppcFpmQ0djM2JrQ1RzY09BTEl6MllqS2dFVGdoX2xvSkt4SWZieVFNLUtiVXJxN1ByeFVWRlJVZ2FZaU01S0UzNmdpTXMyejM3MGxZeDFTRnNqRlVYVjBFVVUxVWJqZTJOVF9SWFJWU0ctWGZzY0Fvb3ZTT2trWWxhcFJkUnpQb1hoVEFtMnd2RW1mVUNtbFJZTmZWNGZCcVIxWjdtUUE?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T03:41:09+00:00", "published_display": "14 Jul 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to earnings forward of Kodiak Sciences, Inc. \u2013 LS:A2N6P0", "summary": "This article provides access to the \"Price to earnings forward\" data for Kodiak Sciences, Inc. (stock symbol A2N6P0) on the TradingView platform. It highlights that the market was closed and no trades were made at the time of viewing, indicating a data point rather than a market ", "url": "https://www.tradingview.com/symbols/LS-A2N6P0/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T15:39:33", "published_display": "10 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Inc (KOD) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live stock quotes and charts for Kodiak Sciences Inc (KOD) on NASDAQ, showing a current price of $40.63 with a slight daily decrease. It also includes information on analyst ratings (though none are available), and highlights that earnings information is not cu", "url": "https://timothysykes.com/quote/KOD/", "source_name": "timothysykes.com", "published_at": "2026-07-09T21:11:54", "published_display": "09 Jul 2026 21:11", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KODIAK SCIENCES INC (KOD) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTE5kenJ3NnYxNHktaXNoc3RJdjVEdDN0M2J5TGJOVGpudFV3QnBiX3ZKTFczUmlPMkY5YjhrcXQzam5vYVB3ZFYxempIT3VIcW1tcnd1Vm5zc29BdUk3akVRREF1RQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-08T22:26:01+00:00", "published_display": "08 Jul 2026 22:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Kodiak Sciences\u2019 (KOD) Shift Into Russell Growth Indices Reframing Its Core Investment Story?", "summary": "Kodiak Sciences Inc. (KOD) has been reclassified from Russell value and microcap indices to Russell growth indices, including the Russell 2000 Growth and Russell 3000 Growth. This reclassification primarily affects the investor base rather than altering the company's fundamental ", "url": "https://www.sahmcapital.com/news/content/is-kodiak-sciences-kod-shift-into-russell-growth-indices-reframing-its-core-investment-story-2026-07-04", "source_name": "Sahm", "published_at": "2026-07-06T05:09:30", "published_display": "06 Jul 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Kodiak Sciences Inc. (KOD)", "summary": "This article examines the historical performance of Kodiak Sciences Inc. (KOD) stock for investors, detailing what a $1,000 investment would be worth over different periods. It highlights the company's focus as a precommercial, retina-focused biotechnology firm with a pipeline of", "url": "https://www.stocktitan.net/tools/stock-return-calculator/KOD", "source_name": "Stock Titan", "published_at": "2026-07-04T05:40:08", "published_display": "04 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Kodiak Sciences Inc. Insider Trading Activity", "summary": "Kodiak Sciences Inc. director Richard S. Levy was granted 17,731 stock options with an exercise price of $38.96 per share, expiring on June 29, 2036. These options will vest on the earlier of June 30, 2027, or one day before the next annual shareholder meeting, provided Levy rema", "url": "https://www.stocktitan.net/sec-filings/KOD/form-4-kodiak-sciences-inc-insider-trading-activity-332745024810.html", "source_name": "Stock Titan", "published_at": "2026-07-02T22:09:44", "published_display": "02 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Kodiak Sciences (KOD) receives 17,731 stock options award", "summary": "Kodiak Sciences Inc. director Robert Profusek was granted 17,731 stock options with an exercise price of $38.96 per share, expiring on June 29, 2036. These options will fully vest on the earlier of June 30, 2027, or the day before the company's next annual meeting, provided he re", "url": "https://www.stocktitan.net/sec-filings/KOD/form-4-kodiak-sciences-inc-insider-trading-activity-82b5cc69d0a8.html", "source_name": "Stock Titan", "published_at": "2026-07-02T22:09:44", "published_display": "02 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Kodiak Sciences Inc For: 2 July By Investing.com", "summary": "Investing.com reported on a Form 4 filing for Kodiak Sciences Inc. for July 2nd. The article provides the company name and filing date, alongside various market data and other news headlines, suggesting a brief update on financial regulatory disclosures related to Kodiak Sciences", "url": "https://ca.investing.com/news/stock-market-news/form-4-kodiak-sciences-inc-for-2-july-93CH-4719257", "source_name": "Investing.com Canada", "published_at": "2026-07-02T21:41:00", "published_display": "02 Jul 2026 21:41", "sentiment": "positive", "sentiment_pct": 60, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "17,731 Kodiak Sciences (KOD) options granted tied to Baker funds", "summary": "Kodiak Sciences director Felix J. Baker was granted 17,731 non-qualified stock options with a strike price of $38.96 per share, which are linked to Baker-affiliated funds. These options, vesting on the earlier of one year post-grant or before the next annual meeting, are issued u", "url": "https://www.stocktitan.net/sec-filings/KOD/form-4-kodiak-sciences-inc-insider-trading-activity-33210a8ee64a.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:09:44", "published_display": "02 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences (KOD) director receives grant of 17,731 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPNVlTa0thZTZ3blhrMFhnVWtLNF9pOVRrdVBaOWxRQ3RWaXJHUnF0SjVBWFFMX1czRHhiNEVidHpvSTdoTUR6QTJjNTQwSjdKcEtQUWxLR3o3SEpBY1BJZnJSWGZTOFB6NFhkR2tvckRuLVRXMnhGQVBrTmZWYkx4MzVsR0tlNS1VeVNyd2hEZXMwamx6MHFfZ1ZvRklWV05WQU5SdnJ6WENNUk0yZXRTQTNR?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "17,731 options granted to Kodiak (NASDAQ: KOD) board director", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOd201bm5NYjJEWUZ5RWRUOVRXQjViaEsxWlNvRDZVSTkzdElhcV83d2t1NVBIMnBVQ3lhdGZ5VmNIR2VxcXBUSUpEcXAwVFUzR2t0QVJCb0JyQXhJbUJubmZlSkF0MjIxOWV0Y3hiYmF0R0F5ZWg5YUY2Nm9ZalgtTjRoY0o0V01wNzcxc2VybjhuUlNRNmxsalBVR1dpRHl4MUo3ODlQcWtVTHFtY1pKeTBB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences (KOD) director awarded stock options for 17,731 shares at $38.96", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOdV9haVA2TExRUGJFMDE3NVJ5OUZTZFJDSmkzS1hrSS1vSjhPVndhSmlJTFFNZFhDQ3RLRmgyUjZYSm5jYjVrZUJSb3YwWEpadnNZZ05wcXZLbGR2NU9fcHJBSGtITDdYc2ZUMFV5OGkxV2psUVVBM0lvRmlBYVE0UGxlY0t0VDBhOXZrLTVPb1VIZTUtR2xlVnJNb05IRFZBNl9ITkFyM2ZuclBtUUJLWmh3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Kodiak Sciences Inc \u2013 NASDAQ:KOD", "summary": "The article focuses on the \"Price to book forward\" metric for Kodiak Sciences Inc. under its NASDAQ ticker KOD. It presents financial data for the company within the context of the Health Technology and Biotechnology sectors, as provided by TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-KOD/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T17:10:03", "published_display": "01 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Inc.(NasdaqGM: KOD) dropped from Russell Microcap Index", "summary": "Kodiak Sciences Inc. (NasdaqGM: KOD) has been removed from the Russell Microcap Index, effective June 29, 2026. This news comes alongside several other changes in Russell indices for Kodiak Sciences on the same date, including additions to growth benchmarks and removals from valu", "url": "https://www.marketscreener.com/news/kodiak-sciences-inc-nasdaqgm-kod-dropped-from-russell-microcap-index-ce7f5fdeda8bff21", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T06:41:55", "published_display": "30 Jun 2026 06:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Inc.(NasdaqGM:KOD) added to Russell Small Cap Comp Growth Benchmark", "summary": "Kodiak Sciences Inc. (NasdaqGM:KOD) has been added to the Russell Small Cap Comp Growth Benchmark, impacting its previous classifications within other Russell indices. The company, a precommercial retina-focused biotechnology firm, is developing three late-stage clinical programs", "url": "https://www.marketscreener.com/news/kodiak-sciences-inc-nasdaqgm-kod-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc88f726", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T20:05:00", "published_display": "29 Jun 2026 20:05", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Inc.(NasdaqGM: KOD) added to Russell 3000E Growth Benchmark", "summary": "Kodiak Sciences Inc. (NasdaqGM: KOD) has been added to the Russell 3000E Growth Benchmark. This news follows several other index-related announcements for the company on the same day, including additions to Russell Small Cap Comp Growth and Russell 2000 Growth benchmarks, and rem", "url": "https://www.marketscreener.com/news/kodiak-sciences-inc-nasdaqgm-kod-added-to-russell-3000e-growth-benchmark-ce7f5fdedc80f327", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T08:40:25", "published_display": "29 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Kodiak Sciences Inc \u2013 NASDAQ:KOD", "summary": "This article provides an enterprise value to EBIT forward for Kodiak Sciences Inc (NASDAQ: KOD). It lists the company's stock information, along with various financial and community features available on the TradingView platform. The content primarily focuses on presenting a spec", "url": "https://www.tradingview.com/symbols/NASDAQ-KOD/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T02:09:26", "published_display": "28 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Kodiak Sciences Inc \u2013 NASDAQ:KOD", "summary": "This article provides access to the enterprise value to EBITDA forward financial metric for Kodiak Sciences Inc., trading under the NASDAQ symbol KOD. It indicates that the market is currently closed with no trades. The content is primarily a data placeholder within a financial p", "url": "https://www.tradingview.com/symbols/NASDAQ-KOD/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:10:18", "published_display": "27 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Kodiak Sciences Inc \u2013 NASDAQ:KOD", "summary": "This article displays the forward enterprise value to revenue for Kodiak Sciences Inc. (NASDAQ: KOD). The data indicates that the market was closed at the time of publication, with no trades reported.", "url": "https://www.tradingview.com/symbols/NASDAQ-KOD/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:09:58", "published_display": "26 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Kodiak Sciences Inc \u2013 NASDAQ:KOD", "summary": "This article provides financial data for Kodiak Sciences Inc (NASDAQ: KOD), specifically its price-to-earnings forward ratio. The content states that the market was closed at the time of publication, and no trades were made. It appears to be a stub or a data point from a financia", "url": "https://www.tradingview.com/symbols/NASDAQ-KOD/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T15:09:58", "published_display": "26 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences, Inc. Actuals & Estimates (NASDAQ:KOD)", "summary": "This article provides an overview of Kodiak Sciences Inc. (NASDAQ: KOD) stock, detailing its current price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report date, and recent revenue and net ", "url": "https://www.tradingview.com/symbols/NASDAQ-KOD/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:40:45", "published_display": "26 Jun 2026 07:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KOD - Kodiak Sciences Inc Options", "summary": "This article provides a comprehensive overview of Kodiak Sciences Inc. (KOD) stock performance and financial data. It includes key metrics such as market capitalization, income, sales, P/E ratios, insider and institutional ownership, profitability, and various performance indicat", "url": "https://finviz.com/stock?t=KOD&ta=1&p=w&ty=oc&r=y2&ov=chain_strike&s=65", "source_name": "Finviz", "published_at": "2026-06-25T14:39:58", "published_display": "25 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KOD - Kodiak Sciences Inc Volatility & Greeks", "summary": "This article provides a detailed financial snapshot of Kodiak Sciences Inc (KOD), including its market capitalization, income, sales, key financial ratios, stock performance metrics, and analyst recommendations. It highlights the company's significant year-over-year stock perform", "url": "https://finviz.com/stock?t=KOD&ty=ocv&ov=list_strike&s=44", "source_name": "Finviz", "published_at": "2026-06-24T13:41:20", "published_display": "24 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Inc (KOD) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Kodiak Sciences Inc (KOD), based on analysis from 7 analysts. The current target price for KOD is USD 64.000, representing a 79.22% upside, with most analysts recommending a \"Buy\" trend. The report also details past EPS performance a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kod/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T21:09:41", "published_display": "18 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Inc (KOD) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of Kodiak Sciences Inc.'s (KOD) financial health, focusing on profitability and balance sheet metrics. It notes that relevant data for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not yet been disclo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kod/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T09:39:54", "published_display": "18 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Inc (KOD) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Kodiak Sciences Inc. (KOD), presenting data on institutional shareholdings and recent changes in those holdings. It lists key institutional investors like Baker Bros. Advisors LP and BlackRock, along with their shar", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kod/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:17", "published_display": "17 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Inc (KOD) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Kodiak Sciences Inc (KOD), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. The analysis indicates that relevant data for these valuation metrics has not yet been disclosed by the company. It serves as a brief overview of", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kod/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:17", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences: Clinical Redemption Is Turning Into Platform Leverage (NASDAQ:KOD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNQk9URVZVVld1Z0JBX0xGdFVhUlQ2WlM3NGdZOWdsQUdZc2taSHJ5LTFxemRaOHI4X3BTY1lTZUJvdktwaHFpVzZVX2FTU2xLRERPenJWLWdqaE1jNHlSckFQUmlyU0NlbEhMMzBPenp4d0FKRWQ2VDZscThlcVVqV09RT1ptWjlGdkRkYkdNZTN3OGhuS2VncEZZQWtpX0hjc2NMRVEzY3NMTlNCbHRr?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should Know", "summary": "", "url": "https://finance.yahoo.com/m/49ec93b4-3620-3216-a518-2686cf1674cd/kodiak-cfo-sells-%241-million.html", "source_name": "Motley Fool", "published_at": "2026-06-10T00:04:25+00:00", "published_display": "10 Jun 2026 00:04", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences (KOD) Is Down 15.4% After Strong Zenkuda GLOW2 Data And Accelerated Filing Plans", "summary": "Kodiak Sciences (KOD) experienced a 15.4% stock drop despite presenting strong Phase III GLOW2 data for its ophthalmology candidate Zenkuda and announcing accelerated regulatory filing plans. The company's investment narrative hinges on Zenkuda and its ABC platform transforming i", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kodiak-sciences-kod-down-15-131851811.html", "source_name": "Market source", "published_at": "2026-06-07T05:09:57", "published_display": "07 Jun 2026 05:09", "sentiment": "negative", "sentiment_pct": 36, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Zenkuda Trial Win Puts Cash Needs And Growth In Focus", "summary": "Kodiak Sciences reported positive phase III results for its drug candidate Zenkuda in diabetic retinopathy, accelerating regulatory submissions. This success could make Zenkuda Kodiak's first commercial product, but the company faces challenges with less than one year of cash run", "url": "https://www.sahmcapital.com/news/content/kodiak-sciences-zenkuda-trial-win-puts-cash-needs-and-growth-in-focus-2026-06-05", "source_name": "Sahm", "published_at": "2026-06-06T19:10:00", "published_display": "06 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences CFO John Borgeson sold $1.02 million in NASDAQ:KOD shares", "summary": "Kodiak Sciences CFO John Borgeson sold 30,000 shares of Kodiak Sciences Inc. (NASDAQ:KOD) common stock for a total of $1.02 million on June 4, 2026, through a pre-planned trading arrangement. Prior to the sale, Borgeson exercised options to acquire the same number of shares at a ", "url": "https://ng.investing.com/news/insider-trading-news/kodiak-sciences-cfo-john-borgeson-sold-102-million-in-nasdaqkod-shares-93CH-2546686", "source_name": "Investing.com Nigeria", "published_at": "2026-06-06T16:39:10", "published_display": "06 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak (KOD) CFO sells 30,000 shares under 10b5-1 trading plan", "summary": "Kodiak Sciences Inc. CFO, John A. Borgeson, executed an exercise-and-sell transaction involving 30,000 common shares. He acquired these shares by exercising stock options at $1.04 per share and then sold them in open-market transactions at weighted-average prices of $34.01 and $3", "url": "https://www.stocktitan.net/sec-filings/KOD/form-4-kodiak-sciences-inc-insider-trading-activity-35c0eafcd014.html", "source_name": "Stock Titan", "published_at": "2026-06-05T21:39:07", "published_display": "05 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KOD News | KODIAK SCIENCES INC (NASDAQ:KOD)", "summary": "This article provides news and stock information for Kodiak Sciences Inc. (NASDAQ: KOD). It highlights a 35% stock rise over three months and announces Kodiak Sciences' participation in the 2026 Jefferies Global Healthcare Conference.", "url": "https://www.chartmill.com/stock/quote/KOD/news", "source_name": "ChartMill", "published_at": "2026-06-05T17:09:01", "published_display": "05 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQck9EX0RQeDNLUmlHMW9QcTZpeENnX2U4NmlYRjNZcUp2WnA1Z3lYc2dwd1ZYc0h5RmFUejgycnZYZXc4aWtvSjAtN3NFbjBoLUVzNHdhbGxRUTFqdVZvRGlLNmQ3dHRxa2g1d1l1NFhkWDRTLWtHT25pX0VYeEFJeGsyNnpFV2QyMFA3WVhrVEgxZw?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kodiak-sciences-present-2026-jefferies-220900591.html", "source_name": "PR Newswire", "published_at": "2026-05-28T22:09:00+00:00", "published_display": "28 May 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally", "summary": "", "url": "https://finance.yahoo.com/m/771db47b-4534-3e90-93ec-eb0c5f75969e/why-one-healthcare-fund.html", "source_name": "Motley Fool", "published_at": "2026-05-17T20:17:13+00:00", "published_display": "17 May 2026 20:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Chardan Upgrades Kodiak Sciences to Buy From Neutral, Raises Price Target to $61 From $14", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/chardan-upgrades-kodiak-sciences-buy-125424574.html", "source_name": "MT Newswires", "published_at": "2026-05-11T12:54:24+00:00", "published_display": "11 May 2026 12:54", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At Kodiak Sciences (KOD) Valuation After Positive Phase 3 GLOW2 Results For Zenkuda", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/look-kodiak-sciences-kod-valuation-011417629.html", "source_name": "Simply Wall St.", "published_at": "2026-05-11T01:14:17+00:00", "published_display": "11 May 2026 01:14", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenkuda Phase 3 Win and Expanding Pipeline Might Change The Case For Investing In Kodiak Sciences (KOD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOVng0UVNldDJBSTBjU3hJVThjaU9JbHhteWxrdmVjQWdWcHlfcTEtSE5KdjM5TDQ5dFVQRFRkdENTdWpCc09XZEhMMkIzVk1pZ0dtUnFiQjR3SnR5V0pLMEY2NUZ5RHlENGJmSjRzMFB5Z3B4TzFQMkF0dVkybE5sTUg2eklNdHZNVXNJOXU4Mll0UHVJZG53QWVKLTkyc0k?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eye drug data from Taiwan cohort backs Kodiak Phase 3 expansion", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOMVBob1docmVIXzI3NHNRTDhsWTQ3d3ZtZm1RaVpna1JZNVEtZWZMM0NKdGl0YWUxb0FMdVFmX29MQnNjclBUTENCQ1NsWThSUXMtWUloOE80S1VYY19aX2NKY0VZVC1GV09DeFEyYWdxTHotaTNnTTJKTTI5QVA4NFBmMTNmay1kdFIwTjk3WFhybHJfSjF1YnpZTGdkUUJYSG5PRmFjRFJNVHlOaFlYRTBnUXdJamNJRWFB?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNOTRCTE1UaUlCTk5DcmJiRmdzSkdwVkt0aXNXRGlyR1JXM0FxRnBWVWZEYndYajdDc2lXMDdtRUkwRXdOeDZIZGZ6dWp4VmpSYkZRU25qZ1k1WERPV181ZldobEhUTDBNeWM1VV9QbjUyS1JoUDZPUERLZWJkSy1NSFgxR0xjY0llREdqQ0ROaVY2czhpRUdF?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kodiak Sciences KOD Stock Soars On Phase 3 Win", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE5lOVVzVHBFSkNQTllibW5uUHFGZy1DNTZzZVdEZDFrVkRlY0NvZVZURXE4ZHpqTUJWUWpzdjROR21oRmw1TjRlbDh6ZlplZy1jQTdMZUV3X3JKeGhRc3FQQklJak9hWnZDTF85N05XU2JNdzNRN1RlWGtDWm15cFk?oc=5", "source_name": "timothysykes.com", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Kodiak Sciences (KOD) Valuation After Recent Share Price Momentum And Conflicting Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxORnNtQlFxalkyLXZKYjVjREVYYkZnUDMxTWxUQUNhUnFQXzNzOUhtWDVfSEN1ZE80SjdBcUlhYk9obkhYMUZHcnJaWFFOSHAxaXdkWlV0aXl3akFhRmhDZWhXR0RBbEVCOG4yWE9YTVpSdUxLYnJZRGgxXzJKaUxQZUVsTGZFbnZ3eXJhdW93cVRzUU5FTkFaQVZTc2FQMkQwcmlaZWFtNA?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Stock Soars Amid Positive Phase 3 Findings\u200b", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE84cmw4OUtoNjNfQUxJNFVvSDJ4Mk1wT3haWFVtMDFBZFc0Y1ExNHpDRTNTUEpwck1BRHpoSTl0bjlod09iYVpUNWU1aDJVZHVIbzN2NzFyYnFrY1BEb0lXNTVianFlRUdFS3VJVmtfdGJfVzJicno4Ty1FUQ?oc=5", "source_name": "StocksToTrade", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences: Road To $120", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOSzBoOGdfWi1NNUZ0SER6TzFOZE5CYmZjMzZHUG9tbWpzSUhlekpqSXlsb1FhbmJQMk96X2ktRGhqaV9Ud25BbGVuUzVWVWRWbDJUZHpUX1BtX09KMVJtay1fZmptOWotc29mazNLX2N1bXBlSzZFUnAtUmhIRDYtWGZCdnlqZVlSSk1XUmtMZw?oc=5", "source_name": "Forbes", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kodiak Sciences shares soar after eye drug succeeds in late-stage study", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxQYjFrUGdFMkRwZUo1ZnV1VV9OUmhrS3daMHNmbUJoNjg3Z2JVS0tOckJGeklET1d0aDNYNkt5LTQxaGhRU3ozaC1vUml4SWNabWtUNWpMYXBoOGFsTDF4NmpkanhnTmtmOWxWS1JpdW9mT3U5TXczdkRxLUZtVFJ0d3Nfd2JjNkU3LXdyVl9FVk1NelJnQ19Td21uU1JWSk1ZdmUtRlVkZ2o5X0VRRlY4anlxSzZUV3BlWjhwLUQxbDFLQkNncUpTNUl3OXJaZm5Dc2Q2ZFdWMWE?oc=5", "source_name": "Reuters", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences stock soars over 60%: what\u2019s behind the sharp rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQczZlMnI1T1RvWThTbzdielN4bUpydUVtRVd4TFB2RnRMUlloeE41aHY3WFpWVVprS096bV9KZzlBVlQzS0Q1OVhGWHlFQl9fVVVscWR3R181ZldDeG5aRUN1M3pMcjlncUQ3ZXZhby1PdUFZaUhhcjFwTVA2MjZRN24xalNFSUZuYnZCQ1UxdlEwamdXVmVNYmFBSlZqeEttWkE?oc=5", "source_name": "Invezz", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences (KOD) Climbs 75% on Stellar Clinical Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPVXFMdmRmT05IdUpLdW5ROHpWQkpBbUs5VHBBbnlDUlB5NFBhcFZvYkxfYjNDNGR2THFISjdwLUNUUVk0dE0tRmlpT2xkRW1LRk9QR0x1YTBKT0R2RGZDRjBMVlFnS0Z6TUlRSTdRVkdpTm5qamhtNE9UZWZMc0R0V3hwclRpVlZpOHY2Q1Q3Z2dTUVRNQlJwb0J0OXhXbVU?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak eye drug cut sight-threatening complications 85% in Phase 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPUE14NnY5UmhhVEZfN1UyUlZGemR1eVh1Y19sQ2lncjQ3NVJBa2dJdEplZFBfYWFjMlpDY1FJMjg3a3RRblVlQXdxZnNTUWRTSTFvQXM2SGxEX2w5Y1pOekVKMjdMOUtkXzhpb2VZdVh6c0xzVko5OUVkQUctNE14Y29XOHYzYWFfRlc5OWZXUlBoak5wSllHOWtkM2toUzRrY3BIYWF0dDZDNU1laHlMV1FIeE9tLXpD?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Inc (KOD) Stock Price Today: $43.26", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE9KdzNBTU1uTVE5TzNmaU4zekVydHc1WW81bk9BQkVkd2kwTDV6OHZ6MW5hTkNmU090VGM3NVJLbE1vWUkzUW12WERXQ3lUYXpfT0lqc2JR?oc=5", "source_name": "Gotrade", "published_at": "2026-02-02T02:57:37+00:00", "published_display": "02 Feb 2026 02:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Dow, S&P 500, Nasdaq Futures Rise After Trump\u2019s 10-Day Iran Pause: Why META, DJT, U, KOD, MDGL Are Trending After-Hours", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOZFFaTFpONXJlMV9wR2hQSU5mRTU3S3FQWjYwVmxSNFppcFpmQ0djM2JrQ1RzY09BTEl6MllqS2dFVGdoX2xvSkt4SWZieVFNLUtiVXJxN1ByeFVWRlJVZ2FZaU01S0UzNmdpTXMyejM3MGxZeDFTRnNqRlVYVjBFVVUxVWJqZTJOVF9SWFJWU0ctWGZzY0Fvb3ZTT2trWWxhcFJkUnpQb1hoVEFtMnd2RW1mVUNtbFJZTmZWNGZCcVIxWjdtUUE?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T03:41:09+00:00", "published_display": "14 Jul 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Kodiak Sciences, Inc. \u2013 LS:A2N6P0", "summary": "This article provides access to the \"Price to earnings forward\" data for Kodiak Sciences, Inc. (stock symbol A2N6P0) on the TradingView platform. It highlights that the market was closed and no trades were made at the time of viewing, indicating a data point rather than a market ", "url": "https://www.tradingview.com/symbols/LS-A2N6P0/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T15:39:33", "published_display": "10 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Inc (KOD) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live stock quotes and charts for Kodiak Sciences Inc (KOD) on NASDAQ, showing a current price of $40.63 with a slight daily decrease. It also includes information on analyst ratings (though none are available), and highlights that earnings information is not cu", "url": "https://timothysykes.com/quote/KOD/", "source_name": "timothysykes.com", "published_at": "2026-07-09T21:11:54", "published_display": "09 Jul 2026 21:11", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KODIAK SCIENCES INC (KOD) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTE5kenJ3NnYxNHktaXNoc3RJdjVEdDN0M2J5TGJOVGpudFV3QnBiX3ZKTFczUmlPMkY5YjhrcXQzam5vYVB3ZFYxempIT3VIcW1tcnd1Vm5zc29BdUk3akVRREF1RQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-08T22:26:01+00:00", "published_display": "08 Jul 2026 22:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Kodiak Sciences\u2019 (KOD) Shift Into Russell Growth Indices Reframing Its Core Investment Story?", "summary": "Kodiak Sciences Inc. (KOD) has been reclassified from Russell value and microcap indices to Russell growth indices, including the Russell 2000 Growth and Russell 3000 Growth. This reclassification primarily affects the investor base rather than altering the company's fundamental ", "url": "https://www.sahmcapital.com/news/content/is-kodiak-sciences-kod-shift-into-russell-growth-indices-reframing-its-core-investment-story-2026-07-04", "source_name": "Sahm", "published_at": "2026-07-06T05:09:30", "published_display": "06 Jul 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Kodiak Sciences Inc. (KOD)", "summary": "This article examines the historical performance of Kodiak Sciences Inc. (KOD) stock for investors, detailing what a $1,000 investment would be worth over different periods. It highlights the company's focus as a precommercial, retina-focused biotechnology firm with a pipeline of", "url": "https://www.stocktitan.net/tools/stock-return-calculator/KOD", "source_name": "Stock Titan", "published_at": "2026-07-04T05:40:08", "published_display": "04 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Kodiak Sciences Inc. Insider Trading Activity", "summary": "Kodiak Sciences Inc. director Richard S. Levy was granted 17,731 stock options with an exercise price of $38.96 per share, expiring on June 29, 2036. These options will vest on the earlier of June 30, 2027, or one day before the next annual shareholder meeting, provided Levy rema", "url": "https://www.stocktitan.net/sec-filings/KOD/form-4-kodiak-sciences-inc-insider-trading-activity-332745024810.html", "source_name": "Stock Titan", "published_at": "2026-07-02T22:09:44", "published_display": "02 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Kodiak Sciences (KOD) receives 17,731 stock options award", "summary": "Kodiak Sciences Inc. director Robert Profusek was granted 17,731 stock options with an exercise price of $38.96 per share, expiring on June 29, 2036. These options will fully vest on the earlier of June 30, 2027, or the day before the company's next annual meeting, provided he re", "url": "https://www.stocktitan.net/sec-filings/KOD/form-4-kodiak-sciences-inc-insider-trading-activity-82b5cc69d0a8.html", "source_name": "Stock Titan", "published_at": "2026-07-02T22:09:44", "published_display": "02 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Kodiak Sciences Inc For: 2 July By Investing.com", "summary": "Investing.com reported on a Form 4 filing for Kodiak Sciences Inc. for July 2nd. The article provides the company name and filing date, alongside various market data and other news headlines, suggesting a brief update on financial regulatory disclosures related to Kodiak Sciences", "url": "https://ca.investing.com/news/stock-market-news/form-4-kodiak-sciences-inc-for-2-july-93CH-4719257", "source_name": "Investing.com Canada", "published_at": "2026-07-02T21:41:00", "published_display": "02 Jul 2026 21:41", "sentiment": "positive", "sentiment_pct": 60, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "17,731 Kodiak Sciences (KOD) options granted tied to Baker funds", "summary": "Kodiak Sciences director Felix J. Baker was granted 17,731 non-qualified stock options with a strike price of $38.96 per share, which are linked to Baker-affiliated funds. These options, vesting on the earlier of one year post-grant or before the next annual meeting, are issued u", "url": "https://www.stocktitan.net/sec-filings/KOD/form-4-kodiak-sciences-inc-insider-trading-activity-33210a8ee64a.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:09:44", "published_display": "02 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences (KOD) director receives grant of 17,731 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPNVlTa0thZTZ3blhrMFhnVWtLNF9pOVRrdVBaOWxRQ3RWaXJHUnF0SjVBWFFMX1czRHhiNEVidHpvSTdoTUR6QTJjNTQwSjdKcEtQUWxLR3o3SEpBY1BJZnJSWGZTOFB6NFhkR2tvckRuLVRXMnhGQVBrTmZWYkx4MzVsR0tlNS1VeVNyd2hEZXMwamx6MHFfZ1ZvRklWV05WQU5SdnJ6WENNUk0yZXRTQTNR?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "17,731 options granted to Kodiak (NASDAQ: KOD) board director", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOd201bm5NYjJEWUZ5RWRUOVRXQjViaEsxWlNvRDZVSTkzdElhcV83d2t1NVBIMnBVQ3lhdGZ5VmNIR2VxcXBUSUpEcXAwVFUzR2t0QVJCb0JyQXhJbUJubmZlSkF0MjIxOWV0Y3hiYmF0R0F5ZWg5YUY2Nm9ZalgtTjRoY0o0V01wNzcxc2VybjhuUlNRNmxsalBVR1dpRHl4MUo3ODlQcWtVTHFtY1pKeTBB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences (KOD) director awarded stock options for 17,731 shares at $38.96", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOdV9haVA2TExRUGJFMDE3NVJ5OUZTZFJDSmkzS1hrSS1vSjhPVndhSmlJTFFNZFhDQ3RLRmgyUjZYSm5jYjVrZUJSb3YwWEpadnNZZ05wcXZLbGR2NU9fcHJBSGtITDdYc2ZUMFV5OGkxV2psUVVBM0lvRmlBYVE0UGxlY0t0VDBhOXZrLTVPb1VIZTUtR2xlVnJNb05IRFZBNl9ITkFyM2ZuclBtUUJLWmh3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Kodiak Sciences Inc \u2013 NASDAQ:KOD", "summary": "The article focuses on the \"Price to book forward\" metric for Kodiak Sciences Inc. under its NASDAQ ticker KOD. It presents financial data for the company within the context of the Health Technology and Biotechnology sectors, as provided by TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-KOD/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T17:10:03", "published_display": "01 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Inc.(NasdaqGM: KOD) dropped from Russell Microcap Index", "summary": "Kodiak Sciences Inc. (NasdaqGM: KOD) has been removed from the Russell Microcap Index, effective June 29, 2026. This news comes alongside several other changes in Russell indices for Kodiak Sciences on the same date, including additions to growth benchmarks and removals from valu", "url": "https://www.marketscreener.com/news/kodiak-sciences-inc-nasdaqgm-kod-dropped-from-russell-microcap-index-ce7f5fdeda8bff21", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T06:41:55", "published_display": "30 Jun 2026 06:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Inc.(NasdaqGM:KOD) added to Russell Small Cap Comp Growth Benchmark", "summary": "Kodiak Sciences Inc. (NasdaqGM:KOD) has been added to the Russell Small Cap Comp Growth Benchmark, impacting its previous classifications within other Russell indices. The company, a precommercial retina-focused biotechnology firm, is developing three late-stage clinical programs", "url": "https://www.marketscreener.com/news/kodiak-sciences-inc-nasdaqgm-kod-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc88f726", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T20:05:00", "published_display": "29 Jun 2026 20:05", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Inc.(NasdaqGM: KOD) added to Russell 3000E Growth Benchmark", "summary": "Kodiak Sciences Inc. (NasdaqGM: KOD) has been added to the Russell 3000E Growth Benchmark. This news follows several other index-related announcements for the company on the same day, including additions to Russell Small Cap Comp Growth and Russell 2000 Growth benchmarks, and rem", "url": "https://www.marketscreener.com/news/kodiak-sciences-inc-nasdaqgm-kod-added-to-russell-3000e-growth-benchmark-ce7f5fdedc80f327", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T08:40:25", "published_display": "29 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Kodiak Sciences Inc \u2013 NASDAQ:KOD", "summary": "This article provides an enterprise value to EBIT forward for Kodiak Sciences Inc (NASDAQ: KOD). It lists the company's stock information, along with various financial and community features available on the TradingView platform. The content primarily focuses on presenting a spec", "url": "https://www.tradingview.com/symbols/NASDAQ-KOD/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T02:09:26", "published_display": "28 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Kodiak Sciences Inc \u2013 NASDAQ:KOD", "summary": "This article provides access to the enterprise value to EBITDA forward financial metric for Kodiak Sciences Inc., trading under the NASDAQ symbol KOD. It indicates that the market is currently closed with no trades. The content is primarily a data placeholder within a financial p", "url": "https://www.tradingview.com/symbols/NASDAQ-KOD/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:10:18", "published_display": "27 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Kodiak Sciences Inc \u2013 NASDAQ:KOD", "summary": "This article displays the forward enterprise value to revenue for Kodiak Sciences Inc. (NASDAQ: KOD). The data indicates that the market was closed at the time of publication, with no trades reported.", "url": "https://www.tradingview.com/symbols/NASDAQ-KOD/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:09:58", "published_display": "26 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Kodiak Sciences Inc \u2013 NASDAQ:KOD", "summary": "This article provides financial data for Kodiak Sciences Inc (NASDAQ: KOD), specifically its price-to-earnings forward ratio. The content states that the market was closed at the time of publication, and no trades were made. It appears to be a stub or a data point from a financia", "url": "https://www.tradingview.com/symbols/NASDAQ-KOD/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T15:09:58", "published_display": "26 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences, Inc. Actuals & Estimates (NASDAQ:KOD)", "summary": "This article provides an overview of Kodiak Sciences Inc. (NASDAQ: KOD) stock, detailing its current price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report date, and recent revenue and net ", "url": "https://www.tradingview.com/symbols/NASDAQ-KOD/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:40:45", "published_display": "26 Jun 2026 07:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KOD - Kodiak Sciences Inc Options", "summary": "This article provides a comprehensive overview of Kodiak Sciences Inc. (KOD) stock performance and financial data. It includes key metrics such as market capitalization, income, sales, P/E ratios, insider and institutional ownership, profitability, and various performance indicat", "url": "https://finviz.com/stock?t=KOD&ta=1&p=w&ty=oc&r=y2&ov=chain_strike&s=65", "source_name": "Finviz", "published_at": "2026-06-25T14:39:58", "published_display": "25 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KOD - Kodiak Sciences Inc Volatility & Greeks", "summary": "This article provides a detailed financial snapshot of Kodiak Sciences Inc (KOD), including its market capitalization, income, sales, key financial ratios, stock performance metrics, and analyst recommendations. It highlights the company's significant year-over-year stock perform", "url": "https://finviz.com/stock?t=KOD&ty=ocv&ov=list_strike&s=44", "source_name": "Finviz", "published_at": "2026-06-24T13:41:20", "published_display": "24 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Inc (KOD) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Kodiak Sciences Inc (KOD), based on analysis from 7 analysts. The current target price for KOD is USD 64.000, representing a 79.22% upside, with most analysts recommending a \"Buy\" trend. The report also details past EPS performance a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kod/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T21:09:41", "published_display": "18 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Inc (KOD) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of Kodiak Sciences Inc.'s (KOD) financial health, focusing on profitability and balance sheet metrics. It notes that relevant data for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not yet been disclo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kod/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T09:39:54", "published_display": "18 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Inc (KOD) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Kodiak Sciences Inc. (KOD), presenting data on institutional shareholdings and recent changes in those holdings. It lists key institutional investors like Baker Bros. Advisors LP and BlackRock, along with their shar", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kod/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:17", "published_display": "17 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Inc (KOD) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Kodiak Sciences Inc (KOD), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. The analysis indicates that relevant data for these valuation metrics has not yet been disclosed by the company. It serves as a brief overview of", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kod/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:17", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences: Clinical Redemption Is Turning Into Platform Leverage (NASDAQ:KOD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNQk9URVZVVld1Z0JBX0xGdFVhUlQ2WlM3NGdZOWdsQUdZc2taSHJ5LTFxemRaOHI4X3BTY1lTZUJvdktwaHFpVzZVX2FTU2xLRERPenJWLWdqaE1jNHlSckFQUmlyU0NlbEhMMzBPenp4d0FKRWQ2VDZscThlcVVqV09RT1ptWjlGdkRkYkdNZTN3OGhuS2VncEZZQWtpX0hjc2NMRVEzY3NMTlNCbHRr?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should Know", "summary": "", "url": "https://finance.yahoo.com/m/49ec93b4-3620-3216-a518-2686cf1674cd/kodiak-cfo-sells-%241-million.html", "source_name": "Motley Fool", "published_at": "2026-06-10T00:04:25+00:00", "published_display": "10 Jun 2026 00:04", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences (KOD) Is Down 15.4% After Strong Zenkuda GLOW2 Data And Accelerated Filing Plans", "summary": "Kodiak Sciences (KOD) experienced a 15.4% stock drop despite presenting strong Phase III GLOW2 data for its ophthalmology candidate Zenkuda and announcing accelerated regulatory filing plans. The company's investment narrative hinges on Zenkuda and its ABC platform transforming i", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kodiak-sciences-kod-down-15-131851811.html", "source_name": "Market source", "published_at": "2026-06-07T05:09:57", "published_display": "07 Jun 2026 05:09", "sentiment": "negative", "sentiment_pct": 36, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Zenkuda Trial Win Puts Cash Needs And Growth In Focus", "summary": "Kodiak Sciences reported positive phase III results for its drug candidate Zenkuda in diabetic retinopathy, accelerating regulatory submissions. This success could make Zenkuda Kodiak's first commercial product, but the company faces challenges with less than one year of cash run", "url": "https://www.sahmcapital.com/news/content/kodiak-sciences-zenkuda-trial-win-puts-cash-needs-and-growth-in-focus-2026-06-05", "source_name": "Sahm", "published_at": "2026-06-06T19:10:00", "published_display": "06 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences CFO John Borgeson sold $1.02 million in NASDAQ:KOD shares", "summary": "Kodiak Sciences CFO John Borgeson sold 30,000 shares of Kodiak Sciences Inc. (NASDAQ:KOD) common stock for a total of $1.02 million on June 4, 2026, through a pre-planned trading arrangement. Prior to the sale, Borgeson exercised options to acquire the same number of shares at a ", "url": "https://ng.investing.com/news/insider-trading-news/kodiak-sciences-cfo-john-borgeson-sold-102-million-in-nasdaqkod-shares-93CH-2546686", "source_name": "Investing.com Nigeria", "published_at": "2026-06-06T16:39:10", "published_display": "06 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak (KOD) CFO sells 30,000 shares under 10b5-1 trading plan", "summary": "Kodiak Sciences Inc. CFO, John A. Borgeson, executed an exercise-and-sell transaction involving 30,000 common shares. He acquired these shares by exercising stock options at $1.04 per share and then sold them in open-market transactions at weighted-average prices of $34.01 and $3", "url": "https://www.stocktitan.net/sec-filings/KOD/form-4-kodiak-sciences-inc-insider-trading-activity-35c0eafcd014.html", "source_name": "Stock Titan", "published_at": "2026-06-05T21:39:07", "published_display": "05 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KOD News | KODIAK SCIENCES INC (NASDAQ:KOD)", "summary": "This article provides news and stock information for Kodiak Sciences Inc. (NASDAQ: KOD). It highlights a 35% stock rise over three months and announces Kodiak Sciences' participation in the 2026 Jefferies Global Healthcare Conference.", "url": "https://www.chartmill.com/stock/quote/KOD/news", "source_name": "ChartMill", "published_at": "2026-06-05T17:09:01", "published_display": "05 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQck9EX0RQeDNLUmlHMW9QcTZpeENnX2U4NmlYRjNZcUp2WnA1Z3lYc2dwd1ZYc0h5RmFUejgycnZYZXc4aWtvSjAtN3NFbjBoLUVzNHdhbGxRUTFqdVZvRGlLNmQ3dHRxa2g1d1l1NFhkWDRTLWtHT25pX0VYeEFJeGsyNnpFV2QyMFA3WVhrVEgxZw?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kodiak-sciences-present-2026-jefferies-220900591.html", "source_name": "PR Newswire", "published_at": "2026-05-28T22:09:00+00:00", "published_display": "28 May 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally", "summary": "", "url": "https://finance.yahoo.com/m/771db47b-4534-3e90-93ec-eb0c5f75969e/why-one-healthcare-fund.html", "source_name": "Motley Fool", "published_at": "2026-05-17T20:17:13+00:00", "published_display": "17 May 2026 20:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan Upgrades Kodiak Sciences to Buy From Neutral, Raises Price Target to $61 From $14", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/chardan-upgrades-kodiak-sciences-buy-125424574.html", "source_name": "MT Newswires", "published_at": "2026-05-11T12:54:24+00:00", "published_display": "11 May 2026 12:54", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Kodiak Sciences (KOD) Valuation After Positive Phase 3 GLOW2 Results For Zenkuda", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/look-kodiak-sciences-kod-valuation-011417629.html", "source_name": "Simply Wall St.", "published_at": "2026-05-11T01:14:17+00:00", "published_display": "11 May 2026 01:14", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenkuda Phase 3 Win and Expanding Pipeline Might Change The Case For Investing In Kodiak Sciences (KOD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOVng0UVNldDJBSTBjU3hJVThjaU9JbHhteWxrdmVjQWdWcHlfcTEtSE5KdjM5TDQ5dFVQRFRkdENTdWpCc09XZEhMMkIzVk1pZ0dtUnFiQjR3SnR5V0pLMEY2NUZ5RHlENGJmSjRzMFB5Z3B4TzFQMkF0dVkybE5sTUg2eklNdHZNVXNJOXU4Mll0UHVJZG53QWVKLTkyc0k?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eye drug data from Taiwan cohort backs Kodiak Phase 3 expansion", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOMVBob1docmVIXzI3NHNRTDhsWTQ3d3ZtZm1RaVpna1JZNVEtZWZMM0NKdGl0YWUxb0FMdVFmX29MQnNjclBUTENCQ1NsWThSUXMtWUloOE80S1VYY19aX2NKY0VZVC1GV09DeFEyYWdxTHotaTNnTTJKTTI5QVA4NFBmMTNmay1kdFIwTjk3WFhybHJfSjF1YnpZTGdkUUJYSG5PRmFjRFJNVHlOaFlYRTBnUXdJamNJRWFB?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNOTRCTE1UaUlCTk5DcmJiRmdzSkdwVkt0aXNXRGlyR1JXM0FxRnBWVWZEYndYajdDc2lXMDdtRUkwRXdOeDZIZGZ6dWp4VmpSYkZRU25qZ1k1WERPV181ZldobEhUTDBNeWM1VV9QbjUyS1JoUDZPUERLZWJkSy1NSFgxR0xjY0llREdqQ0ROaVY2czhpRUdF?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences KOD Stock Soars On Phase 3 Win", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE5lOVVzVHBFSkNQTllibW5uUHFGZy1DNTZzZVdEZDFrVkRlY0NvZVZURXE4ZHpqTUJWUWpzdjROR21oRmw1TjRlbDh6ZlplZy1jQTdMZUV3X3JKeGhRc3FQQklJak9hWnZDTF85N05XU2JNdzNRN1RlWGtDWm15cFk?oc=5", "source_name": "timothysykes.com", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Kodiak Sciences (KOD) Valuation After Recent Share Price Momentum And Conflicting Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxORnNtQlFxalkyLXZKYjVjREVYYkZnUDMxTWxUQUNhUnFQXzNzOUhtWDVfSEN1ZE80SjdBcUlhYk9obkhYMUZHcnJaWFFOSHAxaXdkWlV0aXl3akFhRmhDZWhXR0RBbEVCOG4yWE9YTVpSdUxLYnJZRGgxXzJKaUxQZUVsTGZFbnZ3eXJhdW93cVRzUU5FTkFaQVZTc2FQMkQwcmlaZWFtNA?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Stock Soars Amid Positive Phase 3 Findings\u200b", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE84cmw4OUtoNjNfQUxJNFVvSDJ4Mk1wT3haWFVtMDFBZFc0Y1ExNHpDRTNTUEpwck1BRHpoSTl0bjlod09iYVpUNWU1aDJVZHVIbzN2NzFyYnFrY1BEb0lXNTVianFlRUdFS3VJVmtfdGJfVzJicno4Ty1FUQ?oc=5", "source_name": "StocksToTrade", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences: Road To $120", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOSzBoOGdfWi1NNUZ0SER6TzFOZE5CYmZjMzZHUG9tbWpzSUhlekpqSXlsb1FhbmJQMk96X2ktRGhqaV9Ud25BbGVuUzVWVWRWbDJUZHpUX1BtX09KMVJtay1fZmptOWotc29mazNLX2N1bXBlSzZFUnAtUmhIRDYtWGZCdnlqZVlSSk1XUmtMZw?oc=5", "source_name": "Forbes", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences shares soar after eye drug succeeds in late-stage study", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxQYjFrUGdFMkRwZUo1ZnV1VV9OUmhrS3daMHNmbUJoNjg3Z2JVS0tOckJGeklET1d0aDNYNkt5LTQxaGhRU3ozaC1vUml4SWNabWtUNWpMYXBoOGFsTDF4NmpkanhnTmtmOWxWS1JpdW9mT3U5TXczdkRxLUZtVFJ0d3Nfd2JjNkU3LXdyVl9FVk1NelJnQ19Td21uU1JWSk1ZdmUtRlVkZ2o5X0VRRlY4anlxSzZUV3BlWjhwLUQxbDFLQkNncUpTNUl3OXJaZm5Dc2Q2ZFdWMWE?oc=5", "source_name": "Reuters", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences stock soars over 60%: what\u2019s behind the sharp rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQczZlMnI1T1RvWThTbzdielN4bUpydUVtRVd4TFB2RnRMUlloeE41aHY3WFpWVVprS096bV9KZzlBVlQzS0Q1OVhGWHlFQl9fVVVscWR3R181ZldDeG5aRUN1M3pMcjlncUQ3ZXZhby1PdUFZaUhhcjFwTVA2MjZRN24xalNFSUZuYnZCQ1UxdlEwamdXVmVNYmFBSlZqeEttWkE?oc=5", "source_name": "Invezz", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences (KOD) Climbs 75% on Stellar Clinical Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPVXFMdmRmT05IdUpLdW5ROHpWQkpBbUs5VHBBbnlDUlB5NFBhcFZvYkxfYjNDNGR2THFISjdwLUNUUVk0dE0tRmlpT2xkRW1LRk9QR0x1YTBKT0R2RGZDRjBMVlFnS0Z6TUlRSTdRVkdpTm5qamhtNE9UZWZMc0R0V3hwclRpVlZpOHY2Q1Q3Z2dTUVRNQlJwb0J0OXhXbVU?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak eye drug cut sight-threatening complications 85% in Phase 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPUE14NnY5UmhhVEZfN1UyUlZGemR1eVh1Y19sQ2lncjQ3NVJBa2dJdEplZFBfYWFjMlpDY1FJMjg3a3RRblVlQXdxZnNTUWRTSTFvQXM2SGxEX2w5Y1pOekVKMjdMOUtkXzhpb2VZdVh6c0xzVko5OUVkQUctNE14Y29XOHYzYWFfRlc5OWZXUlBoak5wSllHOWtkM2toUzRrY3BIYWF0dDZDNU1laHlMV1FIeE9tLXpD?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kodiak Sciences Inc (KOD) Stock Price Today: $43.26", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE9KdzNBTU1uTVE5TzNmaU4zekVydHc1WW81bk9BQkVkd2kwTDV6OHZ6MW5hTkNmU090VGM3NVJLbE1vWUkzUW12WERXQ3lUYXpfT0lqc2JR?oc=5", "source_name": "Gotrade", "published_at": "2026-02-02T02:57:37+00:00", "published_display": "02 Feb 2026 02:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 100, "total_relevant": 60, "sentiment_summary": {"positive": 14, "negative": 6, "neutral": 40, "score": 53, "total": 60, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 19.6, "count": 35}, {"event": "earnings", "label": "Earnings", "weight": 9.35, "count": 19}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.9, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 41.31, "latest_week": "2026-07-10", "one_week_move": 7.2, "four_week_move": 21.3, "twelve_week_move": -8.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.511205, "market_dynamics_buy_signal": false, "relative_strength": 46.712191, "fair_value_gap": 281.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 51.5084, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.2% over one week, +21.3% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "Stock Titan", "count": 10}, {"label": "TradingView", "count": 8}, {"label": "TradingKey", "count": 4}, {"label": "www.marketscreener.com", "count": 3}, {"label": "timothysykes.com", "count": 2}, {"label": "ChartMill", "count": 2}, {"label": "Sahm", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 35}, {"label": "Earnings", "count": 19}, {"label": "Regulatory and legal", "count": 2}, {"label": "Analyst action", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+7.2% over one week, +21.3% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Dow, S&P 500, Nasdaq Futures Rise After Trump\u2019s 10-Day Iran Pause: Why META, DJT, U, KOD, MDGL Are Trending After-Hours"}], "updated_at": "2026-07-16T05:41:42.803799+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}